Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.

Cancer medicine - 1 Aug 2024

Duinkerken Charlotte W, Chiodo Sabrina, Hueniken Katrina, Hauptmann Michael, Jóźwiak Katarzyna, Cheng Dangxiao, Hope Andrew, Liu Geoffrey, Zuur Charlotte L

Abstract excerpt

BACKGROUND: Concomitant high-dose cisplatin with radiotherapy is commonly used for treating head and neck squamous cell carcinoma (HNSCC). Cisplatin, often used with radiotherapy, is known for causing irreversible sensorineural hearing loss, with individual variability suggesting a genetic component. This study aims to enhance the predictive ability of the clinical prediction model for cisplatin-induced hearing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chemoradiotherapy

Share to Cisplatin

Share to Head and Neck Neoplasms

Share to Hearing Loss

Share to Polymorphism, Single Nucleotide

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 39159054
DOI: 10.1002/cam4.7465
PMCID: PMC11332395

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.PMID 39159054Read ↗

Pharmacogenetic strategies to mitigate cisplatin-induced ototoxicity in head and neck cancer: A cost-minimization analysis with the use of GSTP1 c.313A>G genotyping.Semantic proximity Read ↗

Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.Semantic proximity Read ↗

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.Semantic proximity Read ↗

Genetic variants associated with cisplatin-induced ototoxicity.Semantic proximity Read ↗

Pharmacogenomics of cisplatin-induced ototoxicity.Semantic proximity Read ↗

Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.Semantic proximity Read ↗

Navigating the Genetic Risk of Chemotherapy-Induced Hearing Loss in the Stria Vascularis.Semantic proximity Read ↗

Genetic markers of cisplatin-induced hearing loss in children.Semantic proximity Read ↗

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.Semantic proximity Read ↗

Leveraging large-scale datasets and single cell omics data to develop a polygenic score for cisplatin-induced ototoxicity.Semantic proximity Read ↗

Identifying genetic risk variants associated with noise-induced hearing loss based on a novel strategy for evaluating individual susceptibility.Semantic proximity Read ↗

The association between DNA repair genes polymorphisms and cisplatin-induced ototoxicity in cancer patients: a systematic review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.